A novel hypocrellin B derivative for photodynamic therapy-driven cancer immunotherapy via triggering immunogenic cell death
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (82)
Show source-provided references
1. The ever-increasing importance of cancer as a leading cause of premature death worldwide10.1002/cncr.33587 ↗
2. Cancer treatment and survivorship statistics, 201910.3322/caac.21565 ↗
3. Strategically engineered Au(I) complexes for orchestrated tumor eradication via chemo-phototherapy and induced immunogenic cell death10.1038/s41467-024-52458-4 ↗
4. Photodynamic therapy of cancer: an update10.3322/caac.20114 ↗
5. In vivo biological activity of the components of haematoporphyrin derivative10.1038/bjc.1982.94 ↗
6. Photodynamic therapy for cancer10.1038/nrc1071 ↗
7. Photodynamic therapy of cancer: An update
8. Vascular and cellular targeting for photodynamic therapy10.1615/CritRevEukarGeneExpr.v16.i4.10 ↗
9. Vascular effects of photodynamic therapy
10. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
11. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells10.1038/sj.bjc.6603792 ↗
12. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model10.1073/pnas.0709256105 ↗
13. Gollnick S.O., Vaughan L., Henderson B.W. Generation of Effective Antitumor Vaccines Using Photodynamic Therapy 1 n.d.
14. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation
15. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown10.1039/c0pp00294a ↗
16. Exploitation of immune response-eliciting properties of hypocrellin photosensitizer SL052-based photodynamic therapy for eradication of malignant tumors10.1111/j.1751-1097.2009.00610.x ↗
17. Immunogenic cell death in cancer: concept and therapeutic implications10.1186/s12967-023-04017-6 ↗
18. Targeting immunogenic cell stress and death for cancer therapy10.1038/s41573-024-00920-9 ↗
19. Magnetic nanoparticles coated with polyphenols for spatio-temporally controlled cancer photothermal/immunotherapy10.1016/j.jconrel.2020.06.015 ↗
20. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
21. Study of electron transfer interaction between hypocrellin and N,N-diethylaniline by UV–visible, fluorescence, electron spin resonance spectra and time-resolved transient absorption spectra10.1016/1010-6030(95)04270-9 ↗
22. Biophysical evaluation of two red-shifted hypocrellin B derivatives as novel PDT agents10.1016/j.jphotobiol.2008.09.007 ↗
23. Preclinical assessment of hypocrellin B and hypocrellin B derivatives as sensitizers for photodynamic therapy of cancer: progress update10.1111/j.1751-1097.1997.tb01915.x ↗
24. Synthesis of a water-soluble cyclodextrin modified hypocrellin and ESR study of its photodynamic therapy properties10.1039/b202439j ↗
25. In vitro and in vivo antitumor activity of a novel hypocrellin B derivative for photodynamic therapy10.1016/j.pdpdt.2014.01.003 ↗
26. Biodegradable hypocrellin derivative nanovesicle as a near-infrared light-driven theranostic for dually photoactive cancer imaging and therapy10.1016/j.biomaterials.2018.09.021 ↗
27. A novel hypocrellin-based assembly for sonodynamic therapy against glioblastoma10.1039/D1TB01886H ↗
28. Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system10.3892/ijo.2015.3079 ↗
29. Hypocrellin derivative-loaded calcium phosphate nanorods asNIR light-triggered phototheranostic agents with enhanced tumor accumulation for cancer therapy10.1002/cmdc.201900512 ↗
30. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor10.1084/jem.176.6.1693 ↗
31. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis10.1038/sj.cdd.4402201 ↗
32. TLR signaling10.1016/j.smim.2006.12.004 ↗
33. Dendritic cell regulation of T helper cells10.1146/annurev-immunol-101819-025146 ↗
34. Therapeutic cancer vaccines10.1038/s41568-021-00346-0 ↗
35. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice10.1038/cmi.2010.30 ↗
36. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
37. Antigen presentation and T cell stimulation by dendritic cells10.1146/annurev.immunol.20.100301.064828 ↗
38. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity10.1111/j.1600-065X.2008.00718.x ↗
39. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity10.1016/j.immuni.2009.08.001 ↗
40. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
41. Photodynamic therapy and antitumor immunity
42. Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects10.5411/wji.v4.i1.1 ↗
43. Tumor antigen presentation by dermal antigen-presenting cells10.1046/j.1523-1747.2000.00014.x ↗
44. S. Razi, M. Keshavarz-FathiChapter 7 - Whole tumor cell vaccine for cancer, In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy, Academic Press, 2019, pp. 91–99, 10.1016/B978-0-12-814039-0.00007-2..10.1016/B978-0-12-814039-0.00007-2 ↗
45. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy10.1016/j.addr.2009.03.009 ↗
46. PLGA-based nanoparticles: an overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
47. The Ki-67 protein: from the known and the unknown10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 ↗
48. Murine dendritic cell antigen-presenting cell function is not altered by burn injury10.1189/jlb.0408257 ↗
49. Facile phototherapeutic nanoplatform by integrating a multifunctional polymer MnO2 for enhancing tumor synergistic therapy10.1002/adhm.201900414 ↗
50. Using porous CaCO3/hyaluronic acid nanocages to accommodate hydrophobic photosensitizer in aqueous media for photodynamic therapy10.1016/j.colsurfa.2016.12.027 ↗
51. Hypocrellin-loaded gold nanocages with high two-photon efficiency for photothermal/photodynamic cancer therapy in vitro10.1021/nn302634m ↗
52. Synthesis, characterization and photodynamic activity of amino-substituted hypocrellin derivatives10.1562/0031-8655(2001)074<0201:SCAPAO>2.0.CO;2 ↗
53. Synthesis and characterization of three novel amphiphilic aminated hypocrellins as photodynamic therapeutic agents10.1562/0031-8655(2003)078<0411:SACOTN>2.0.CO;2 ↗
54. New potential photodynamic therapeutic anti-cancer agents: synthesis and characterization of demethoxy amino-substituted hypocrellins
55. Synthesis and EPR investigations of new aminated hypocrellin derivatives10.1016/S0891-5849(00)00187-8 ↗
56. Mitochondrial photodamage and PDT-induced apoptosis10.1016/S1011-1344(97)00127-9 ↗
57. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy
58. ER-targeting cyanine de as an NIR photoinducer to efficiently trigger photoimmunogenic cancer cell death10.1021/jacs.1c11886 ↗
59. An antioxidative-enhanced endoplasmic reticulum-targeted cyanine dye for efficient tumor immunotherapy10.1016/j.cej.2024.153089 ↗
60. A lysosomal-targeted Pt(II) metallacycle for NIR-II fluorescence imaging guided highly efficient tumor immunogenic cell death10.1007/s11426-024-2176-7 ↗
61. Nuclear-targeted nanostrategy regulates spatiotemporal communication for dual antitumor immunity
62. The Achilles’ heel of cancer: targeting tumors via lysosome-induced immunogenic cell death10.1038/s41419-022-04912-8 ↗
63. Activation of apoptosis signalling pathways by reactive oxygen species10.1016/j.bbamcr.2016.09.012 ↗
64. Consensus guidelines for the detection of immunogenic cell death10.4161/21624011.2014.955691 ↗
65. Lysosomal membrane permeabilization and cell death10.1111/tra.12613 ↗
66. Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death10.1128/MCB.24.15.6592-6607.2004 ↗
67. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors10.1016/S0092-8674(00)81589-5 ↗
68. Molecular biology of Bax and Bak activation and action10.1016/j.bbamcr.2010.12.019 ↗
69. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application10.1016/j.apsb.2019.01.011 ↗
70. Remission-stage ovarian cancer cell vaccine with cowpea mosaic virus adjuvant prevents tumor growth10.3390/cancers13040627 ↗
71. Whole tumor antigen vaccines10.1016/j.smim.2010.02.004 ↗
72. Antigen-specific immunotherapy of cervical and ovarian cancer10.1111/j.1600-065X.2008.00622.x ↗
73. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy10.1021/acsnano.8b07371 ↗
74. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer10.1016/j.jconrel.2022.09.013 ↗
75. Biomineralized MnO2 nanoplatforms mediated delivery of immune checkpoint inhibitors with STING pathway activation to potentiate cancer radio-immunotherapy10.1021/acsnano.2c10352 ↗
76. Cryo-shocked cancer cells for targeted drug delivery and vaccination10.1126/sciadv.abc3013 ↗
77. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns10.1038/s41551-021-00795-w ↗
78. Multimodal imaging-guided photothermal immunotherapy based on A Versatile Nir-ii Aggregation-induced Emission Luminogen10.1002/anie.202202614 ↗
79. ER-Targeting PDT converts tumors into in situ therapeutic tumor vaccines10.1021/acsnano.2c01669 ↗
80. Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
81. Semiconducting polymer nano-regulators with cascading activation for photodynamic cancer immunotherapy
82. Enhancement of anti-tumor immunity by photodynamic therapy10.1007/s12026-009-8119-4 ↗